Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$144.46−3.30 (-2.23%)
Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%
Merck price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Merck's price to sales ratio was 5.5× on Nov 10, 2026, against 4.1× a year earlier. Over the last 5 years it ranged from 3.1× to 5.6×, with a median of 4.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 5.5× | +1.4 |
| 2025 | Dec 31, 2025 | 4.1× | +0.1 |
| 2024 | Dec 31, 2024 | 4.0× | −0.7 |
| 2023 | Dec 29, 2023 | 4.7× | −0.1 |
| 2022 | Dec 30, 2022 | 4.8× | +0.6 |
| 2021 | Dec 31, 2021 | 4.2× | −1.5 |
| 2020 | Dec 31, 2020 | 5.7× | +0.6 |
| 2019 | Dec 31, 2019 | 5.1× | +0.2 |
| 2018 | Dec 31, 2018 | 5.0× | +1.1 |
| 2017 | Dec 29, 2017 | 3.9× | −0.2 |
| 2016 | Dec 30, 2016 | 4.1× | +0.3 |
| 2015 | Dec 31, 2015 | 3.8× | −0.1 |
| 2014 | Dec 31, 2014 | 3.9× | +1.1 |
| 2013 | Dec 31, 2013 | 2.7× | +0.1 |
| 2012 | Dec 31, 2012 | 2.6× | +0.3 |
| 2011 | Jan 31, 2011 | 2.3× | −0.2 |
| 2010 | Dec 31, 2010 | 2.5× | – |
See a number that looks wrong?